Invited Review Article
Japanese guidelines for atopic dermatitis 2020,

https://doi.org/10.1016/j.alit.2020.02.006Get rights and content
Under a Creative Commons license
open access

Abstract

Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion, which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin irritability to non-specific stimuli and epicutaneous sensitization. In the lesion site, a further inflammation-related reduction in skin barrier function, enhanced irritability and scratching-related stimuli deteriorate eczema, leading to vicious cycle of inflammation. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Keywords

Atopic dermatitis
Eczema
Clinical practice guidelines
Evidence-based medicine
Treatment

Cited by (0)

This is an abridged edition of “Clinical practice guidelines for the management of atopic dermatitis 2018.” by Katoh N et al. in J Dermatol 2019; 46: 1053–1101.

Peer review under responsibility of Japanese Society of Allergology.

1

Norito Katoh and Yukihiro Ohya, Chairperson and Vice-Chairperson, respectively, of Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018.